Moneycontrol PRO
Contest Alert:Last day to win Amazon vouchers worth Rs 5000. Take the MCPRO Quiz today to grab yours!

Accumulate Glenmark Pharmaceuticals target of Rs 575: Geojit

Geojit recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 575 in its research report dated November 18, 2021.

November 18, 2021 / 03:02 PM IST
  • bselive
  • nselive
Todays L/H

Geojit's research report on Glenmark Pharmaceuticals

Glenmark Pharma Ltd (GNP) is an India-based pharmaceutical company with commercial presence in more than 80 countries across the globe. GNP is primarily focused on generics, specialty and OTC businesses. The company has strong regional/country-specific presence in diabetes, cardiovascular and oral contraceptives. Q2FY22 revenue up 7.5% YoY (+6.1% QoQ) primarily owing to strong performance in the Africa, Asia, and CIS regions (ROW), and Europe. EBITDA grew 6.8% YoY, though margin saw a negligible contraction of 10bps YoY at 18.9% owing to higher operating costs. During the quarter, company paid off a substantial portion of debt on its books using internal accruals and IPO proceeds. We remain cautious of near term performance, esp. in the domestic India business and Americas, as margins may come under stress in the coming quarters with further rise in input costs. Company’s long-term potential however remains positive.


We revise our rating down to ACCUMULATE with a revised TP of Rs. 575 based on 13x FY23E adj. EPS.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Nov 18, 2021 03:02 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark